COMMUNIQUÉS West-GlobeNewswire

WeightWatchers Launches Inaugural Awards, Honoring Top Picks in Health and Wellness Products
12/08/2025
A New Mark of Excellence in Health and Wellness, WeightWatchers Awards Feature Products Curated by Experts and Trusted by Millions of Members NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: [...]
San Diego Charity Golf Tournament at Maderas Golf Club to Support Veterans, First Responders, and NUCCA Awareness
12/08/2025
Dr. Vivek Soham and the Origin Vitae Network Host The Guardian Classic Charity Golf Tournament on September 8th, 2025 SAN DIEGO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- On Monday, September 8th, 2025, the rolling greens of [...]
SoldierStrong Joins Face the Fight® Coalition to Combat Veteran Suicide
12/08/2025
STAMFORD, Conn., Aug. 12, 2025 (GLOBE NEWSWIRE) -- The national nonprofit SoldierStrong has been accepted as a member of the Face the Fight coalition, co-founder and chairman Dr. Chris Meek said today. This partnership [...]
AscellaHealth Ranks No. 535 on the 2025 Inc. 5000 List of America’s Fastest-Growing Private Companies
12/08/2025
With Three-Year Revenue Growth of 755 Percent, This Marks AscellaHealth’s 4th Time on the List BERWYN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Inc., the leading media brand and playbook for the entrepreneurs and business [...]
Health system adoption of AI outpaces internal governance and strategy
12/08/2025
CHICAGO, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Eighty-eight percent of health systems are using Artificial Intelligence internally, and 71% have identified and deployed pilot or full solutions in finance, revenue cycle [...]
Rapid Micro Biosystems Enters into Five-Year, $45 Million Term Loan Facility with Trinity Capital Inc.
12/08/2025
$20 million drawn down at closing, with access to up to an additional $25 million Strengthens Company’s financial position and reinforces ability to achieve positive cash flow LEXINGTON, Mass., Aug. 12, 2025 (GLOBE [...]
Rapid Micro Biosystems Reports Second Quarter 2025 Financial Results
12/08/2025
Reports second quarter 2025 total revenue of $7.3 million , representing 10% growth compared to the second quarter of 2024. Second quarter 2025 recurring revenue increased 15% compared to the second quarter of 2024. [...]
argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis
12/08/2025
Seles speaks out about her diagnosis with MG, a chronic autoimmune disease that causes muscle weakness, which can be severe and significantly impact daily life Partnership with Seles will highlight the ‘Go for Greater’ [...]
TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
12/08/2025
Two-year relapse data from ALLOHA™ Phase 1 heme trial to be presented by end of year Expects to dose first solid tumor patients with multiplex TCR-T in the third quarter of 2025 Cash, cash equivalents, and marketable [...]
NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues
12/08/2025
Conference call will be held today, Tuesday, August 12 at 9:00 am ET CARMEL, Ind., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company [...]
Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights
12/08/2025
Completed dosing of FTD-GRN Cohort 2 in upliFT-D study Reported updated interim data showing that PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease [...]
Altimmune Announces Second Quarter 2025 Financial Results and Business Update
12/08/2025
Positive data from the IMPACT Phase 2b trial reinforces the potential for pemvidutide to be a highly differentiated MASH therapy Pemvidutide is the first product candidate to achieve statistically significant MASH [...]
Endure Biotherapeutics Receives SBIR Phase I Grant to Advance Engineered Native Bacteria Therapy for Familial Adenomatous Polyposis
12/08/2025
San Diego, Aug. 12, 2025 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE Endure Biotherapeutics Receives SBIR Phase I Grant to Advance Engineered Native Bacteria Therapy for Familial Adenomatous Polyposis SAN DIEGO – August [...]
Adverum Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Pipeline Highlights
12/08/2025
- ARTEMIS Phase 3 trial enrollment exceeding expectations; driven by strong retina specialist and patient enthusiasm for a potential One And Done™ therapy for wet AMD - ARTEMIS enrollment completion expected in 1Q 2026 [...]
Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for Registrational Trial of AXPAXLI™ in NPDR
12/08/2025
Ocular plans to outline clinical trial design, timing, and development strategy for non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME) at its Investor Day on September 30, 2025 BEDFORD, Mass [...]
SRx Health Solutions Initiates Restructuring Proceedings under CCAA for its Canadian Subsidiary
12/08/2025
U.S. operations, including Halo subsidiary, will not be affected by CCAA Proceedings; No U.S. bankruptcy filing expected TAMPA, Fla., Aug. 12, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) ( [...]
Tilray Expands Hemp-Derived Delta-9 THC Beverage Lineup with 10mg Drinks from Fizzy Jane’s and Happy Flower Brands
12/08/2025
NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc . (“Tilray”) (NASDAQ: TLRY and TSX: TLRY) is building on the momentum of its hemp-derived Delta-9 THC (HDD9) beverage portfolio with new 10mg format [...]
Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update
12/08/2025
Reached full enrolment of Phase 1b study evaluating GT-02287 in Parkinson’s Disease (PD) with or without GBA1 mutations during 2Q 2025, earlier than anticipated Analysis of functional changes and biomarker activity at [...]
Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates
12/08/2025
— Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 on track for the second half of 2025 — Completed dosing of over 80% of planned REWRITE healthy volunteers across multiple single ascending dose (SAD) [...]

Pages